Reno County, Kansas Issues Community Health Alert Ahead of July 1 Kratom Prohibition

Why it matters

Reno County's public health alert reflects the practical challenges states face when prohibiting a substance that many residents have been using therapeutically — for pain, opioid withdrawal, and mental health. The alert's emphasis on naloxone distribution and fentanyl awareness highlights how a kratom ban can paradoxically increase overdose risk if users shift to other substances.

The big picture

Kansas passed legislation in 2026 classifying kratom (mitragynine) and 7-OH (7-hydroxymitragynine) as controlled substances, effective July 1. Reno County — located in south-central Kansas — issued an early community alert on June 3, emphasizing that residents who stop using kratom abruptly face opioid-like withdrawal and may be at risk if they turn to other substances, including counterfeit pills laced with fentanyl.

Key findings

• Kansas law effective July 1, 2026 bans possession and sale of kratom and 7-OH
• Kratom users may experience withdrawal symptoms similar to opioid withdrawal: anxiety, irritability, restlessness, muscle aches, nausea, and insomnia
• Authorities recommend naloxone (Narcan) for anyone who stops using kratom due to its opioid-like mechanism of action
• Residents can dispose of kratom at no-questions-asked prescription drug collection boxes or local police departments
• Medication-assisted treatment (MAT) is available through local providers for those seeking help

What they say

The Reno Recovery Collaborative stated: "Individuals use kratom for a variety of reasons, including managing pain, reducing opioid use, coping with withdrawal symptoms, or self-treating mental health concerns. Regardless of why someone uses kratom, abruptly stopping use or switching to another substance can increase health risks, including the risk of overdose."

Bottom line

Reno County's June 2026 community alert ahead of Kansas's kratom ban signals a broader public health challenge: as states prohibit kratom, health agencies must prepare for withdrawal cases and prevent users from transitioning to more dangerous opioids or counterfeit pills.